Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date18 Mar 1985 |
Comparison of the effects of Bimatoprost 0.01% and Timolol 0.5% on circadian intraocular pressure
Treatment of macular edema secondary to central or branch vein occlusion by dexamethazone intravitreal injection
Comparison of Incidence and Severity of conjunctival hyperemia associated with use of topical Bimatoprost 0.01% and latanoprost 0.005% in Glaucoma or Ocular Hypertensive patients
100 Clinical Results associated with Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca
0 Patents (Medical) associated with Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca
100 Deals associated with Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca
100 Translational Medicine associated with Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca